Board of Directors
Board of Directors
Our Board of Directors comprises five outside directors and two internal directors, totaling seven directors (as of June 30, 2024). In principle, the Board holds 10 regular Board meetings per year. Each meeting of the Board of Directors involves lively discussions and deliberations in a solemn atmosphere, where globally-minded outside directors with a wealth of management experience ask questions and give advice on the execution of operations by executive officers from various angles. The Board of Directors also works to obtain necessary information as appropriate on the developments in significant legal revisions and trends in corporate governance through lectures given by outside experts and other means.
In fiscal 2023, the Board of Directors was comprised of five independent directors, including two female independent directors, and two internal directors. Board of Directors’ meetings were convened 10 times, with 100% attendance by all directors.
Based on the Board of Directors Regulations, the Board of Directors not only addresses statutory matters but also reviews the medium- to long-term business portfolio, approves quarterly budgets and quarterly earnings reports, deliberates on M&A projects and the executive organization, and receives reports on the activity status and medium- to long-term plans of each business division. Once a year, the members of the Board of Directors and the three committees are asked to evaluate themselves through a survey on their operations and effectiveness. A summary of the results of the evaluations for fiscal 2023 is as follows:
Based on a common understanding of the importance of the Board of Directors being composed of appropriate members and to fulfil its function of monitoring and supervising execution, the Board of Directors is highly regarded as having improved its operational aspects, with open and active discussions under appropriate agenda setting by the chairperson. The Nomination Committee, Compensation Committee, and Audit Committee are also highly regarded as having adequate discussions with appropriate numbers and compositions of members. With regard to the matters identified as key issues in the evaluations of the effectiveness of the Board of Directors in fiscal 2022, (namely(1) more detailed discussion of key management issues, including discussion on medium- to long-term strategy, (2) more detailed discussion of formation of a CEO succession plan, and (3) more detailed discussion of risks associated with issues of sustainability), it is assessed that certain measures have been taken but that further efforts are needed. Particularly with regard to (1), the Board of Directors is expected to have more detailed discussion on the medium- to long-term growth strategy and the direction of the Company's overall portfolio."
In order to discuss each issue, the Company will continue to examine and improve the operation of the Board of Directors, communication among directors and between directors and executive officers, and the composition of the Board of Directors. It will thus aim to further improve the effectiveness of the Board of Directors.
Board Member Profiles
Lead Independent Director,
Chairperson of the Audit Committee,
Member of the Nomination Committee,
Member of the Compensation Committee,
Member of the Healthcare Compliance Committee
Hiroaki Yoshihara
(Born on Feb. 9, 1957)
-
[Number of years in office of the Director of the Company]
6 years
-
[Number of shares of the Company held]
0 Share
-
[Number of attendances to the board meetings]
10/10 times (100%)
Independent Director,
Chairperson of the Nomination Committee,
Member of the Compensation Committee,
Member of the Audit Committee,
Member of the Healthcare Compliance Committee
Yasuyuki Abe
(Born on Apr. 17, 1952)
-
[Number of years in office of the Director of the Company]
3 years
-
[Number of shares of the Company held]
0 share
-
[Number of attendances to the board meetings]
10/10 times (100%)
Independent Director,
Member of the Nomination Committee,
Member of the Compensation Committee,
Member of the Audit Committee
Takayo Hasegawa
(Born on Oct. 15, 1959)
-
[Number of years in office of the Director of the Company]
2 years
-
[Number of shares of the Company held]
0 share
-
[Number of attendances to the board meetings]
10/10 times (100%)
Independent Director,
Chairperson of the Healthcare Compliance Committee,
Member of the Nomination Committee,
Member of the Compensation Committee,
Member of the Audit Committee,
Mika Nishimura
(Born on Aug. 14, 1963)
-
[Number of years in office of the Director of the Company]
2 years
-
[Number of shares of the Company held]
0 share
-
[Number of attendances to the board meetings]
10/10 times (100%)
Independent Director,
Chairperson of the Compensation Committee,
Member of the Nomination Committee,
Member of the Audit Committee,
Mototsugu Sato
(Born on Oct. 17, 1956)
-
[Number of years in office of the Director of the Company]
1 year
-
[Number of shares of the Company held]
0 share
-
[Number of attendances to the board meetings]
10/10 times (100%)
Director, Representative Executive Officer, President & CEO
Chairperson of the Board of Directors
Eiichiro Ikeda
(Born on Mar. 17, 1970)
-
[Number of years in office of the Director of the Company]
2 years
-
[Number of shares of the Company held]
2,900 shares
-
[Number of attendances to the board meetings]
10/10 times (100%)
Director, Representative Executive Officer & CFO
Ryo Hirooka
(Born on Jan. 14, 1974)
-
[Number of years in office of the Director of the Company]
2 years
-
[Number of shares of the Company held]
9,700 shares
-
[Number of attendances to the board meetings]
10/10 times (100%)
Please see the website for further details.